Evans, R. J. Courtenay; Howard, A. N.; Hyams, D. E.
January 1973
Angiology;Jan1973, Vol. 24 Issue 1, p22
Academic Journal
Secholex� (PDX chloride) is a palatable anion exchange resin which is effective alone but better tolerated than Questran�. When the anion exchange resins were combined with clofibrate, synergism occurred. Simultaneous dosage of Secholex� (15 g/day) and clofibrate (1.5 g/day) was effective in all patients studied and produced a mean fall in plasma cholesterol of 35% which was sustained with prolonged treatment. The combination of clofibrate with Questran� was less effective and gave it mean decrease of only 17%. The administration of Secholex� with or without clofibrate is particularly useful in the treatment of patients with type II hyperlipoproteinaemia.


Related Articles

  • When should we screen children for hyperlipidemia? Misicko, Nancy E.; St. Anna, Leillani // Journal of Family Practice;Aug2006, Vol. 55 Issue 8, p723 

    The article provides information about hyperlipidemia. Children should be screened for hyperlipidemia when there is a history of familial hypercholesterolemia. Patients with a strong family history of lipid disorders or familial hypercholesterolemia should have more directed education on...

  • Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. Derfler, Kurt; Steiner, Sabine; Sinzinger, Helmut // Wiener Klinische Wochenschrift;Aug2015, Vol. 127 Issue 15/16, p655 

    The prevalence of familial disorders of lipid metabolism in Europe is higher than believed so far. In severely affected patients in whom conventional combined lipid lowering agents are insufficient to achieve target values, patients being intolerant to all the available members of the statin...

  • How do I treat case of xanthelasmata? Orteu, Catherine // Pulse;3/3/2003, Vol. 63 Issue 9, p72 

    Answers a question on how to treat a case of xanthelasmata. Signs and symptoms; Treatment options; Lack of evidence that cholesterol reduction affects the appearance of xanthelasmata.

  • Familial hypercholesterolaemia: clinical features and management. Pottle, Alison // Nursing Standard;12/14/2005, Vol. 20 Issue 14-16, p55 

    Coronary heart disease is the leading cause of mortality and morbidity in the UK, for which hypercholesterolaemia is a risk factor. This article concentrates on the management of patients with familial hypercholesterolaemia (FH). It discusses FR, how it is diagnosed, and the treatments that are...

  • Screening of APOB Gene Mutations in Subjects with Clinical Diagnosis of Familial Hypercholesterolemia. Meriño-ibarra, Erardo; Castillo, Sergio; Mozas, Pilar; Cenarro, Ana; Martorell, Esperanza; Díaz, JosÉ Luis; Suarez-Tembra, Manuel; Alonso, Rodrigo; Civeira, Fernando; Mata, Pedro; Pocoví, Miguel // Human Biology;Oct2005, Vol. 77 Issue 5, p663 

    Monogenic hypercholesterolemia is a group of lipid disorders, most of which have autosomal dominant transmission. Familial defective apoB (FDB) resulting from mutations in the APOB gene is a well-recognized cause of autosomal dominant monogenic hypercholesterolemia (ADMH). However, the frequency...

  • Prickly Pear Fruit Pulp Improves Platelet Function in Small Human Trial. Webb, Denise // HerbalGram;Winter2005, Issue 65, p33 

    Presents a study which examines the effect of prickly pear fruit pulp in healthy volunteers and patients with mild familial heterozygous hypercholesterolemia on various parameters of platelet function. Association of the disturbance in glucose and lipid metabolism to impaired platelet function;...

  • Mutation detection in Chinese patients with familial hypercholesterolemia. Du, Ran; Fan, Liang-Liang; Lin, Min-Jie; He, Zhi-Jian; Huang, Hao; Chen, Ya-Qin; Li, Jing-Jing; Xia, Kun; Zhao, Shui-Ping; Xiang, Rong // SpringerPlus;12/12/2016, Vol. 5 Issue 1, p1 

    Background: Familial hypercholesterolemia (FH) is the first molecularly and clinically characterized genetic disease of lipid metabolism. It is an autosomal dominant disorder with significantly elevated levels of total cholesterol and low density of lipoprotein cholesterol in serum, which would...

  • Ezetimibe/Simvastatin: A Review of its Use in the Management of Hypercholesterolemia. Murdoch, David; Scott, Lesley J. // American Journal of Cardiovascular Drugs;2004, Vol. 4 Issue 6, p405 

    Ezetimibe/simvastatin (Inegyâ„¢, Vytorinâ„¢) therapy combines two lipid-lowering compounds with complementary mechanisms of action, thereby blocking the two sources of plasma cholesterol and improving lipid profiles. Thus, intestinal absorption of dietary cholesterol and related...

  • Long-term effects of policosanol on obese patients with Type II Hypercholesterolemia. Mas, R.; Castaño, G.; Fernández, J.; Gamez, R.; Illnait, J.; Fernandez, L.; Lopez, E.; Mesa, M.; Alvarez, E.; Mendoza, S. // Asia Pacific Journal of Clinical Nutrition;2004 Supplement, Vol. 13, pS102 

    Both hypercholesterolemia (HC) and obesity are coronary risk factors. Clinical studies have shown the benefits of lowering elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C) on clinical end-points. Policosanol is a cholesterol-lowering drug purified from sugar cane wax with a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics